Aperio Group’s KALA BIO KALA Stock Holding History

Aperio Group’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$100K	Buy	6 +2	+50%	+$37.6K	﹤0.01%	2380
2020 Q3	$78K	Buy	+4	New	+$91.9K	﹤0.01%	2334

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aperio Group's KALA Position: Q4 2020 in Review

Aperio Group increased its KALA BIO (KALA) stake by 50% in Q4 2020, buying an estimated $37.6K and bringing the position to 6 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Aperio Group first reported a position in KALA in Q3 2020 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold KALA as of Q4 2020.

Aperio Group held 6 shares of KALA BIO worth $100K as of Q4 2020.
Aperio Group bought 2 KALA BIO shares in Q4 2020, an estimated $37.6K.
KALA BIO made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2380 holding.
Aperio Group first reported a position in KALA BIO in Q3 2020 and has held it in 2 quarters since.
112 funds tracked by Wall St. Rank held KALA BIO as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.